Government and Private Sector's Initiatives to Raise Awareness About SCD to Drive Global Sickle Cell Disease Treatment Market During 2022–2030

According to our latest study on " Sickle Cell Disease Treatment Market Forecast to 2030 – Global Analysis –Treatment, Route of Administration, and Distribution Channel," the market is expected to grow from US$ 1,160.16 million in 2022 to US$ 4,691.87 million by 2030; it is estimated to grow at a CAGR of 19.1% during 2022–2030. The market growth is primarily attributed to increasing prevalence of sickle cell disease and the government and private sector's initiatives to raise awareness about sickle cell disease. However, lack of sickle cell disease treatment options are hindering the market growth.

Sickle cell disease awareness campaigns help enhance the knowledge of the population regarding the disease, thereby promoting healthcare services through intersectoral collaboration and social support. Governments of several countries are taking various initiatives to create awareness and conduct research for the development of new SCD drugs and vaccines. Governments of various countries across the globe with a high prevalence of sickle cell disease are deploying various strategies to eradicate the diseases by improving access to healthcare services, including treatment options, to the people. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the SCD drug/vaccine pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of sickle cell disease.

A few SCD drugs/vaccines that are under clinical development are mentioned in the table below:

                                   Sickle Cell Disease Drugs/Vaccine/Compounds Under Clinical Development

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of SCD drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Increasing Prevalence of Sickle Cell Disease to Bolster Sickle Cell Disease Treatment Market Growth

The treatment plan for sickle cell disease (SCD) can be divided into two categories: maintaining health and treating complications. Sickle cell anemia has genotypic and phenotypic variants that are based on unique mutations in hemoglobin genes. There is a high prevalence of the disease as well as a rise in its severity across the globe. According to the WHO, approximately 5% of the world's population has genes inhibiting hemoglobin diseases such as sickle cell anemia and thalassemia. According to a study on sickle cell disease published in the National Library of Medicine, more than 300,000 babies are born with severe hemoglobin disorders each year; also, 400,000 newborns are expected to have sickle cell disease by 2050. In addition, according to a published report in 2023 by the American Society of Hematology, the estimated number of people suffering from SCD in the US is approximately 70,000–100,000. Thus, the rising prevalence of sickle cell disease in different regions across the globe boosts the sickle cell disease treatment market growth.

Novartis AG, Pfizer Inc, Emmaus Life Sciences Inc, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Siklos, Mylan NV, Taj Pharmaceuticals Limited, and Apotex are among the leading companies operating in the sickle cell disease treatment market.

Based on treatment, the sickle cell disease treatment market is segmented into generic drugs and originators. Based on route of administration, the sickle cell disease treatment market is bifurcated into oral and parenteral. Based on distribution channel, the sickle cell disease treatment market is divided into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. By geography, the sickle cell disease treatment market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, Nigeria, Congo, Tanzania, Uganda, Ghana, Kenya, Zambia, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com